Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study

Blood (2016) 128 (22): 181.

https://doi.org/10.1182/blood.V128.22.181.181

Published: 2016

Journal Articles

First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results

Blood (2016) 128 (22): 1826.

https://doi.org/10.1182/blood.V128.22.1826.1826

Published: 2016

Journal Articles

Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial.

Steven M. Horwitz, MD, Madeleine Duvic, MD, Youn Kim, MD, Jasmine M Zain, MD, Mary Jo Lechowicz, MD, Patricia Myskowski, MD, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 919.

https://doi.org/10.1182/blood.V114.22.919.919

Published: 2009

Journal Articles

Pralatrexate (PDX) IS Active in Cutaneous T-Cell Lymphoma: Preliminary Results of a Multi-Center Dose-Finding Trial.

Steven M. Horwitz, MD, Madeleine Duvic, MD, Youn Kim, MD, Jasmine M. Zain, MD, Mary Jo Lechowicz, MD, Patricia Myskowski, MD, Hanna Weissbrot, Danielle Wright, Lacey Chance, Tony Koutsoukos, Pablo Cagnoni, MD, Michael Saunders, MD, Owen A. O’Connor, MD, PhD

Blood (2008) 112 (11): 1569.

https://doi.org/10.1182/blood.V112.11.1569.1569

Published: 2008

Journal Articles

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

Youn Kim, MD, Sean Whittaker, MD, FRCP, Marie France Demierre, MD, Alain H Rook, MD, Adam Lerner, MD, Madeleine Duvic, MD, Sunil Reddy, MD, Ellen J Kim, MD, Tadeusz Robak, MD, Jürgen C Becker, MD, Alexey Samtsov, MD, William McCulloch, MB, FRCP, Archibald G Prentice, MBChB, FRCP, FRCPath

Blood (2008) 112 (11): 263.

https://doi.org/10.1182/blood.V112.11.263.263

Published: 2008

Journal Articles

Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study.

Madeleine Duvic, MD, Andres Forero-Torres, MD, Francine Foss, MD, Elise Olsen, MD, Youn Kim, MD

Blood (2007) 110 (11): 122.

https://doi.org/10.1182/blood.V110.11.122.122

Published: 2007

Journal Articles

Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma: Clinical and Molecular Characterization of a Subset with Worse Outcome.

Denise Woo, MD, Chris Jones, MD, Monique Vanoli-Storz, MD, Sabine Kohler, MD, Sunil Reddy, MD, Ranjana Advani, MD, Richard Hoppe, MD, Youn Kim, MD

Blood (2007) 110 (11): 3573.

https://doi.org/10.1182/blood.V110.11.3573.3573

Published: 2007

Journal Articles

Preliminary Report on a Phase I/II Study of Intratumoral Injection of PF-3512676 (CpG 7909), a TLR9 Agonist, Combined with Radiation in Recurrent Low-Grade Lymphomas.

Wei Yun Z. Ai, MD, PhD, Youn Kim, MD, Richard T. Hoppe, MD, Sumit Shah, Bsc, Sandra J. Horning, MD, Robert Tibshirani, PhD, Ronald Levy, MD

Blood (2006) 108 (11): 2716.

https://doi.org/10.1182/blood.V108.11.2716.2716

Published: 2006

Journal Articles

Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.

Madeleine Duvic, MD, Youn Kim, MD, Sunil Reddy, MD, Andres Forero-Torres, MD, Lauren C. Pinter-Brown, MD, Mark U. Rarick, MD, John Zic, MD, Sophie Worobec, MD, Neil Korman, MD, Timothy Kuzel, MD, Kimberly Bohjanen, MD, Karen Flessland, Jeremy Barton, MD, Eric Sievers, MD

Blood (2006) 108 (11): 2733.

https://doi.org/10.1182/blood.V108.11.2733.2733

Published: 2006

Journal Articles

Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.

Madeleine Duvic, MD, Andres Forero-Torres, MD, Francine Foss, MD, Elsie A. Olsen, MD, Youn Kim, MD

Blood (2006) 108 (11): 2467.

https://doi.org/10.1182/blood.V108.11.2467.2467

Published: 2006

Journal Articles

Immunoregulatory Effects of Allogeneic Mixed Chimerism Induced by T-Cell Depleted, Nonmyeloablative Bone Marrow Transplantation on Chronic Inflammatory Arthritis and Autoimmunity Developed in Interleukin-1 Receptor Antagonist-Deficient Mice.

Seok-Goo Cho, MD, PhD, Min-Chung Park, PhD, So-Youn Min, PhD, Young-Gyu Cho, PhD, Seok Lee, MD, PhD, Mi-La Cho, PhD, Hong-Seok Chang, MD, Jong-Wook Lee, MD, Woo-Sung Min, MD, Ho-Youn Kim, MD, Chun-Choo Kim, MD

Blood (2005) 106 (11): 1277.

https://doi.org/10.1182/blood.V106.11.1277.1277

Published: 2005

Journal Articles

TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909.

Youn Kim, MD, Michael Girardi, MD, Madeline Duvic, MD, Timothy Kuzel, MD, Alain Rook, MD, Brian Link, MD, Lauren Pinter-Brown, MD, Carol Comerci, Sonja McAuley, Tess Schmalbach, MD

Blood (2004) 104 (11): 743.

https://doi.org/10.1182/blood.V104.11.743.743

Published: 2004

NARROW

Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study

First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results

Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial.

Pralatrexate (PDX) IS Active in Cutaneous T-Cell Lymphoma: Preliminary Results of a Multi-Center Dose-Finding Trial.

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study.

Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma: Clinical and Molecular Characterization of a Subset with Worse Outcome.

Preliminary Report on a Phase I/II Study of Intratumoral Injection of PF-3512676 (CpG 7909), a TLR9 Agonist, Combined with Radiation in Recurrent Low-Grade Lymphomas.

Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.

Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.

Immunoregulatory Effects of Allogeneic Mixed Chimerism Induced by T-Cell Depleted, Nonmyeloablative Bone Marrow Transplantation on Chronic Inflammatory Arthritis and Autoimmunity Developed in Interleukin-1 Receptor Antagonist-Deficient Mice.

TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only